Jeito
  • Home
  • About
  • The team
  • Our portfolio
  • Newsroom
  • Contact
  • EnglishEnglish
    • FrançaisFrançais
    • EnglishEnglish
Select Page
Jeito Capital co-leads $156million oversubscribed Series B financing in Quell Therapeutics

Jeito Capital co-leads $156million oversubscribed Series B financing in Quell Therapeutics

by Jeito Life | 29 Nov Mon | English

Quell Therapeutics is the world leader in developing engineered T-regulatory (Tregs) cell therapies for serious medical conditions driven by the immune system. Jeito continues to build a strong portfolio of companies with groundbreaking therapies in areas of high...
Jeito Capital co-leads $156million oversubscribed Series B financing in Quell Therapeutics

Jeito Capital portfolio company SparingVision announces strategic collaboration with Intellia Therapeutics

by Jeito Life | 13 Oct Wed | English

Partnership will allow SparingVision to develop novel genomic medicines for the treatment of ocular diseases utilizing Intellia’s proprietary CRISPR/Cas9 technology Jeito Capital selected SparingVision as its first French investment in October 2020, participating in a...
Jeito Capital becomes Key Player in the Financing of Life Sciences in Europe with the Closing of Jeito I at €534 million ($630 million)

Jeito Capital becomes Key Player in the Financing of Life Sciences in Europe with the Closing of Jeito I at €534 million ($630 million)

by Jeito Life | 20 Sep Mon | English

Oversubscribed Jeito I becomes the largest European fund dedicatedto the life sciences sector. Jeito Capital is dedicated to working with biotech entrepreneurs to provide financial and expert support in continuity to accelerate patients’ access to groundbreaking...
Jeito Capital co-leads $156million oversubscribed Series B financing in Quell Therapeutics

Jeito Capital’s Dr. Rafaèle Tordjman Appointed to Promote the French Biotech Ecosystem

by Jeito Life | 28 Jul Wed | English

The appointment of Dr. Tordjman was granted by French Ministers, Agnès Pannier-Runacher and Franck Riester Paris, France, 28 July 2021 – Jeito Capital (“Jeito”), a rapidly emerging independent Private Equity firm dedicated to biotech and biopharma, today welcomes the...
Jeito Capital becomes key investor in Alentis Therapeutics as part of $67 million Series B financing round

Jeito Capital becomes key investor in Alentis Therapeutics as part of $67 million Series B financing round

by Jeito Life | 15 Jun Tue | English

Jeito Capital selects Alentis Therapeutics as its fifth investment since launching the fund Alentis is focused on the development of breakthrough treatments for fibrotic diseases and associated cancers Paris, France, 15 June 2021 – Jeito Capital (“Jeito”), a rapidly...
« Older Entries

Recent Posts

  • Jeito Capital co-leads $76 million Series A financing for CDR-Life its 10th investment since its launch
  • Jeito Capital co-leads EUR 80 million euro Series B financing in European oncology company, Precirix
  •  Jeito Capital co-leads $65 million Series A financing in EyeBio
  • Jeito Capital announces the appointments of Dr Andreas Wallnoefer as Partner Investor and Isabelle Meyrier as Head of Legal
  • JEITO CAPITAL becomes key investor in NMD Pharma as part of a €35 Million new financing

Recent Comments

    Mentions et autres liens
    We use cookies on our website to provide you with the most relevant experience by remembering your preferences and repeat visits.
    By clicking on "Accept All", you consent to the use of ALL cookies. However, you can visit "Cookie Settings" to provide controlled consent.
    Cookie settingsAccept all
    Manage consent

    Privacy Overview

    This website uses cookies to enhance your experience when browsing the site. Of these, cookies that are categorized as necessary are stored on your browser because they are essential for the basic functionality of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the ability to decline these cookies. But disabling some of these cookies may affect your browsing experience.
    SAVE & ACCEPT